Maximum Tolerated Dose, Safety and Efficacy of Docetaxel / Cisplatin + STI571
Status:
Terminated
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1/Phase 2 study of STI571 combined with docetaxel and cisplatin for treatment
of patients with recurrent and metastatic Non-Small Cell Lung Cancer (NSCLC).
This research study has 2 parts to it. The first part (Phase 1) is called a dose-escalation.
Not all subjects enrolled into this phase of the study will receive the same dose. The
purpose of the dose-escalation is to determine the highest safe dose of STI571 that can be
used in combination with docetaxel and cisplatin. That dose will be used in Phase 2.